YZYinghua Zeng

Yinghua Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yinghua Zeng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Haocheng Wang

    Department of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, China

    1 shared publication
  • Jiale Liu

    Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Jie Zhan

    Nanfang Hospital, Southern Medical University

    1 shared publication
  • Ning Liao

    Department of Breast Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.

    1 shared publication
  • Qiuqun Xiao

    Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Weiqi Zhang

    Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses

    by Weiqi Zhang, Yinghua Zeng, Qiuqun Xiao, Yuanyuan Wu, Jiale Liu, Haocheng Wang, Yuting Luo, Jie Zhan, Ning Liao, Yanbin Cai

    Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors. Herein, a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor (PAC-SABI) is described, which undergoes biomimetic surface propagation on cancer cell membranes through ligand-receptor binding and enzyme-triggered reactions. By simultaneously blocking CD47 and CD24 signaling, PAC-SABI enhances the phagocytic ability of macrophages in vitro and in vivo, promoting anti-tumor responses in breast and pancreatic cancer mouse models. Moreover, building on the foundation of PAC-SABI-induced macrophage repolarization and increased CD8+ T cell tumor infiltration, sequential anti-PD-1 therapy further suppresses 4T1 tumor progression, prolonging survival rate. The in vivo construction of PAC-SABI-based nano-architectonics provides an efficient platform for bridging innate and adaptive immunity to maximize therapeutic potency.